Improving Access to Long-Acting Injectable (LAI) Psychotropic Medications
Long-Acting Injectable (LAI) psychotropic medications have demonstrated improvements in medication adherence, resulting in improved clinical outcomes and reduced risk for higher levels of healthcare utilization.
Antipsychotics are generally used to manage symptoms of Schizophrenia Spectrum and other Psychotic Disorders, but they are also used to treat mood swings (depression and mania). There are two generations of LAI medications: LAI first-generation antipsychotics and LAI second-generation antipsychotics. These medications include: Haldol Decanoate, Fluphenazine Decanoate, Risperdal Consta,® Invega Sustenna,® Abilify Maintena,® Zyprexa Relprevv, Paliperidone Palmitate, and Aristada.®
Feedback from our Health Plan of Nevada (HPN) and Sierra Health and Life (SHL) behavioral health network all point to an opportunity for improving access to LAI medications. Difficulty with access or inability to obtain or administer LAI medications were identified as barriers to treatment and recovery planning for HPN/ SHL members. The HPN behavioral health team is launching the LAI initiative to assist providers and patients in gaining access to LAI medication when clinically appropriate.
Please review the LAI information listed below. Here you will find a quick reference guide and a step-by-step process for obtaining LAI medications through Genoa Healthcare. LAI medications are available to individuals who have HPN or SHL as their medical health plan.